Pub Date : 2001-01-01DOI: 10.1046/J.1525-1411.2001.31007-4.X
T. Gilligan, W. Oh
{"title":"Biochemical Outcome Following External Beam Radiation Therapy With or Without Androgen Suppression Therapy for Clinically Localized Prostate Cancer.","authors":"T. Gilligan, W. Oh","doi":"10.1046/J.1525-1411.2001.31007-4.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2001.31007-4.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"25 1","pages":"45-46"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74506211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2001-01-01DOI: 10.1046/J.1525-1411.2001.003001002.X
G. J. C. M. Kolvenbag
{"title":"The Prostate Cancer Continuum: The Role of Bicalutamide (Casodex®)","authors":"G. J. C. M. Kolvenbag","doi":"10.1046/J.1525-1411.2001.003001002.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2001.003001002.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"55 1","pages":"2-13"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88226054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2001-01-01DOI: 10.1046/J.1525-1411.2001.003001030.X
M. Rosenthal, David M. Thomas, I. Davis, G. Toner, N. Noordin, J. Zalcberg
Objectives: Chemotherapy has an established role in the palliative therapy of patients with hormone-refractory prostate cancer (HRPC). However, optimal chemotherapy for HRPC remains poorly defined. This pilot study examined the activity and toxicity of oral 5-fluorouracil (5-FU) in combination with eniluracil for the treatment of patients with HRPC. Materials and Methods: Eighteen patients with HRPC and painful bone metastases were enrolled, although 1 patient was deemed ineligible because of incidental gastric cancer. The median age was 69 years (range, 57–82 years), median Eastern Cooperative Oncology Group performance status was 1 (range, 0–2) and median prostate specific antigen (PSA) level was 146 μg/l (range 4–2020 μg/l). Eniluracil (10 mg/m2) and 5-FU (1 mg/m2) were given orally, twice daily, for 28 days in 35-day cycles. Results: Two patients (11%) had partial pain responses (95% confidence interval, 0–29%), and 6 patients (35%) had stable pain for a minimum of 8 weeks. A reduction in analgesic use occurred in four patients (23%), and five patients (29%) experienced stable analgesic use. A partial PSA response (>50% reduction on at least two occasions, 5 weeks apart) was achieved in three patients (18%), and eight patients (48%) had stable PSA responses (PSA was rising pretreatment). Grade 4 diarrhea occurred in one patient. Grade 3 toxicities were as follows: anemia, 1 patient; lethargy, 1 patient; and deterioration in liver function, 1 patient. Conclusions: Oral eniluracil/5-FU is well tolerated in this patient population but has only modest activity. Studies in combination with other active agents may be warranted in patients with HRPC.
{"title":"Pilot Study of Oral Eniluracil/5-FU in the Palliation of Hormone-Refractory Prostate Cancer","authors":"M. Rosenthal, David M. Thomas, I. Davis, G. Toner, N. Noordin, J. Zalcberg","doi":"10.1046/J.1525-1411.2001.003001030.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2001.003001030.X","url":null,"abstract":"Objectives: Chemotherapy has an established role in the palliative therapy of patients with hormone-refractory prostate cancer (HRPC). However, optimal chemotherapy for HRPC remains poorly defined. This pilot study examined the activity and toxicity of oral 5-fluorouracil (5-FU) in combination with eniluracil for the treatment of patients with HRPC. Materials and Methods: Eighteen patients with HRPC and painful bone metastases were enrolled, although 1 patient was deemed ineligible because of incidental gastric cancer. The median age was 69 years (range, 57–82 years), median Eastern Cooperative Oncology Group performance status was 1 (range, 0–2) and median prostate specific antigen (PSA) level was 146 μg/l (range 4–2020 μg/l). Eniluracil (10 mg/m2) and 5-FU (1 mg/m2) were given orally, twice daily, for 28 days in 35-day cycles. Results: Two patients (11%) had partial pain responses (95% confidence interval, 0–29%), and 6 patients (35%) had stable pain for a minimum of 8 weeks. A reduction in analgesic use occurred in four patients (23%), and five patients (29%) experienced stable analgesic use. A partial PSA response (>50% reduction on at least two occasions, 5 weeks apart) was achieved in three patients (18%), and eight patients (48%) had stable PSA responses (PSA was rising pretreatment). Grade 4 diarrhea occurred in one patient. Grade 3 toxicities were as follows: anemia, 1 patient; lethargy, 1 patient; and deterioration in liver function, 1 patient. Conclusions: Oral eniluracil/5-FU is well tolerated in this patient population but has only modest activity. Studies in combination with other active agents may be warranted in patients with HRPC.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"35 1","pages":"30-35"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79790214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2001-01-01DOI: 10.1046/J.1525-1411.2001.003001014.X
W. Oh
{"title":"Anemia Related to Hormonal Ablation Therapy for Prostate Cancer","authors":"W. Oh","doi":"10.1046/J.1525-1411.2001.003001014.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2001.003001014.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"43 1","pages":"14-17"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90667806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2001-01-01DOI: 10.1046/J.1525-1411.2001.003001042.X
T. Gilligan, W. Oh
{"title":"Bicalutamide Monotherapy Compared with Castration in Patients with Nonmetastatic Locally Advanced Prostate Cancer: 6.3 Years of Follow‐up","authors":"T. Gilligan, W. Oh","doi":"10.1046/J.1525-1411.2001.003001042.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2001.003001042.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"60 1","pages":"42-43"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80266154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2001-01-01DOI: 10.1046/J.1525-1411.2001.31007-3.X
T. Gilligan, W. Oh
{"title":"Prospective Trial of the Herbal Supplement PC‐SPEC in Patients with Progressive Prostate Cancer.","authors":"T. Gilligan, W. Oh","doi":"10.1046/J.1525-1411.2001.31007-3.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2001.31007-3.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"112 1","pages":"44-45"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85105553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2001-01-01DOI: 10.1046/J.1525-1411.2001.31007-2.X
T. Gilligan, W. Oh
{"title":"Overall Survival after Prostate‐Specific‐Antigen‐Detected Recurrence Following Conformal Radiation Therapy.","authors":"T. Gilligan, W. Oh","doi":"10.1046/J.1525-1411.2001.31007-2.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2001.31007-2.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"11 1","pages":"43-44"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73704979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-12-01DOI: 10.1046/J.1525-1411.2000.24009.X
N.N.K. Lynn, G. N. Collins, K. Alexandrou, S. Brown, P. Brooman, P. O’Reilly
Introduction: Serum prostate specific antigen at the cutoff levels of 4 ng/ml has low specificity for prostate cancer. We evaluated various PSA parameters (i.e., total PSA density [tPSAD], free PSA density [fPSAD], the ratio of free to total PSA [f/t ratio], and age-specific PSA) in terms of cancer diagnosis and reducing the number of negative results for prostatic biopsies. Materials and Methods: A series of 305 patients was studied. Serum tPSA and fPSA levels were measured. Prostate volume was measured with transrectal ultrasound, and sextant biopsies were performed. The f/t ratio, tPSAD, and fPSAD were calculated. Sensitivity and specificity were calculated for age-specific PSA. Receiver operating characteristic curve analysis was used to analyze the diagnostic performance of these PSA parameters. A subpopulation of patients with serum PSA levels between 4 and 10 ng/ml also was analyzed with a specific view to reducing negative results of biopsies. The Mann-Whitney U test was used to analyze the difference in these parameters between patients with benign and malignant histologies. Results: There was significant difference in these PSA parameters between patients with benign and malignant histologies (p < 0.05). tPSAD had the largest area under the curve for total population as well as for patients with tPSA levels between 4 and 10 ng/ml. Although the f/t ratio had a larger area under the curve than did tPSA assay in patients with PSA levels between 4 and 10 ng/ml, the difference was not statistically significant. Using a tPSAD of 0.12 ng/ml/ml as the cutoff level of negative results of prostate biopsies could be reduced by 37% in patients with PSA levels between 4 and 10 ng/ml. Although the f/t ratio could reduce negative results of biopsies by 33.8% at the cutoff value of 0.26, 15.6% of cancers would be missed. Age-specific PSA could reduce 31% of negative prostatic biopsies, but 28% of cancers would be missed. Using combined tPSAD and the f/t ratio did not improve reductions of negative biopsy results. Conclusion: tPSA density has the highest sensitivity and specificity in differentiating benign from malignant prostates. By using tPSA density, negative results of prostate biopsies can be reduced by 37%, while missing only a small number of cancers.
{"title":"Comparative Analysis of the Role of Prostate Specific Antigen Parameters in Clinical Practice","authors":"N.N.K. Lynn, G. N. Collins, K. Alexandrou, S. Brown, P. Brooman, P. O’Reilly","doi":"10.1046/J.1525-1411.2000.24009.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2000.24009.X","url":null,"abstract":"Introduction: Serum prostate specific antigen at the cutoff levels of 4 ng/ml has low specificity for prostate cancer. We evaluated various PSA parameters (i.e., total PSA density [tPSAD], free PSA density [fPSAD], the ratio of free to total PSA [f/t ratio], and age-specific PSA) in terms of cancer diagnosis and reducing the number of negative results for prostatic biopsies. \u0000 \u0000 \u0000 \u0000Materials and Methods: A series of 305 patients was studied. Serum tPSA and fPSA levels were measured. Prostate volume was measured with transrectal ultrasound, and sextant biopsies were performed. The f/t ratio, tPSAD, and fPSAD were calculated. Sensitivity and specificity were calculated for age-specific PSA. Receiver operating characteristic curve analysis was used to analyze the diagnostic performance of these PSA parameters. A subpopulation of patients with serum PSA levels between 4 and 10 ng/ml also was analyzed with a specific view to reducing negative results of biopsies. The Mann-Whitney U test was used to analyze the difference in these parameters between patients with benign and malignant histologies. \u0000 \u0000 \u0000 \u0000Results: There was significant difference in these PSA parameters between patients with benign and malignant histologies (p < 0.05). tPSAD had the largest area under the curve for total population as well as for patients with tPSA levels between 4 and 10 ng/ml. Although the f/t ratio had a larger area under the curve than did tPSA assay in patients with PSA levels between 4 and 10 ng/ml, the difference was not statistically significant. Using a tPSAD of 0.12 ng/ml/ml as the cutoff level of negative results of prostate biopsies could be reduced by 37% in patients with PSA levels between 4 and 10 ng/ml. Although the f/t ratio could reduce negative results of biopsies by 33.8% at the cutoff value of 0.26, 15.6% of cancers would be missed. Age-specific PSA could reduce 31% of negative prostatic biopsies, but 28% of cancers would be missed. Using combined tPSAD and the f/t ratio did not improve reductions of negative biopsy results. \u0000 \u0000 \u0000 \u0000Conclusion: tPSA density has the highest sensitivity and specificity in differentiating benign from malignant prostates. By using tPSA density, negative results of prostate biopsies can be reduced by 37%, while missing only a small number of cancers.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"10 1","pages":"205-210"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91044931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-12-01DOI: 10.1046/J.1525-1411.2000.24005-2.X
G. Bubley
{"title":"Benefit of Adjuvant Radiation Therapy for Localized Prostate Cancer with a Positive Surgical Margin.","authors":"G. Bubley","doi":"10.1046/J.1525-1411.2000.24005-2.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2000.24005-2.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78611450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-12-01DOI: 10.1046/J.1525-1411.2000.24001.X
D. Reese, E. Small
{"title":"Therapy of Advanced Prostate Cancer Part II: Response End Points and the Use of Chemotherapy","authors":"D. Reese, E. Small","doi":"10.1046/J.1525-1411.2000.24001.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2000.24001.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"5 1","pages":"173-178"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88830149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：